Qualcomm Incorporated

Huawei Technologies Co., Limited

Chinese Academy of Sciences

Shanghai Jiaotong University

Other

Nokia Solutions and Networks Oy

Ge Lighting Solutions LLC

Sichuan University

Fudan University

General Electric Company

Nokia Technologies Oy

Sony Group Corporation

Firmenich Sa

Electronic Arts Inc.

Delta Electronics (shanghai) Co., Ltd

Jian Li

Shuhui Chen

Guoping Hu

Charles Z Ding

Haiying He

Jie Li

Peng Li

Lihong Hu

Kevin X Chen

Hong Tao Liu

Hualiang Jiang

Kaixian Chen

Changlong Xu

Zhiyong Wang

Jiang Wang

Wentao Wu

Peng Zhang

Dengke Cai

Fei Wang

Xiaolin Li

Jia Tao Li

Bin Chen

Huisheng Zhou

Yu Zhang

Fang Liu

Bing Li

Chao Wei

Jilei Hou

Liangming Wu

Yunfu Luo

Chengde Wu

Chen Zhang

Lei Zhang

Hao Xu

Hao Wu

Yuan Chen

Yong Wang

Thomas Clynne

Fei Sun

Xipeng Zhu

Xing Liu

Yu Chen Zhou

Gary Robert Allen

Ruiming Zheng

Xiao Xun Zhang

Xiquan Zhang

Kun Xiao

Kai Zhou

Hongwei Li

Jun Yin

Dageng Chen

Feng Gao

Benjamin Lee Yoder

Jing Jiang

Thomas J Richardson

Chen Sun

Peng Cheng

Chenxi Hao

Xiaoyan Bi

Yan Wang

Yan Chen

Jian Wang

Yong Liang Liu

Jinfa Zhang

Qiaoyu Li

Jing Li

Nevenka Dimitrova

Yi Liu

Liang Jie Xu

Xin Wang

Wei Huang

Wei Wang

Jian Zhou

Tao Cui

Yi Chen

Jun Zhu

Zheng Wang

Jing Wang

Yang Zhang

Peng Wu

Liang Hu

Hui Chen

Chun Sing Li

Dan Geng

Ling Yang

Hongjiang Xu

Lu Zhang

Fang Quan Xie

Bhaskar Bhupalam

Wei Gu

Lu Lu

Tie-Lin Wang

Dong Zhang

Angel Janevski

Dan Li

Disclosed are a series of benzopyrimidine compounds and a use thereof, and specifically disclosed are compounds represented by formula (II) and pharmaceutically acceptable salts thereof.

Benzopyrimidine compounds and use thereof

Disclosed are the solid form, crystalline form, crystal form A of a compound of formula (I), and a preparation method therefor, crystal form B and a preparation method therefor. Also disclosed are use of the solid form, crystalline form, crystal form A, and crystal form B in the preparation of drugs for the treatment of diseases related to FGFR.

FGFR inhibitor compound in solid form and preparation method therefor

A Spiro compound serving as an ERK inhibitor, and an application thereof in preparing a drug for treating an ERK-related disease. The present invention specifically relates to a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.

Spiro compound serving as ERK inhibitor, and application thereof

Methods, systems, and devices for wireless communication are described. Generally, the described techniques provide for sending, from an upper layer at a transmitting device to a lower layer at the transmitting device, an indication by which the lower layer determines that a packet is to be transmitted as either an initial transmission or as a retransmission. The lower layer at the transmitting device may then determine a transmission process for transmitting the packet based on the indication, and the transmitting device may transmit the packet in accordance with the transmission process. Because the lower layer may identify whether the packet is to be transmitted as either the initial transmission or the retransmission, the lower layer may adapt the transmission process to improve the chances that the packet is received by a receiving device or to limit overhead.

Assistance signaling for radio link control retransmissions

Disclosed are a pyrrolopyrimidine compound and a use thereof in preparing a medicine for diseases related to a BTK protein kinase inhibitor. Specially, disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt thereof.

Pyrrolopyrimidine compound as BTK inhibitor and use thereof

Disclosed is a class of porcupine inhibitors, specifically a compound as represented by formula (I), and a pharmaceutically acceptable salt or an isomer thereof.

Compound as porcupine inhibitor and use thereof

Provided are a crystal of a compound of formula (I), salt thereof, a crystal of the salt thereof, and a preparation method for the crystal. Also comprised are applications of the compound and the crystal in preparation of drugs for treating IRAK4-related diseases.

IRAK4 inhibitor crystal and preparation method therefor

The present invention relates to a pyrrolopyrimidine compound used as a JAK inhibitor, and the use thereof in the preparation of a drug for treating a JAK1- and/or JAK2-associated disease, and in specifically relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Pyrrolopyrimidine compound and use thereof

The present disclosure relates to an electronic device, a wireless communication method, and a computer-readable storage medium. The electronic device according to the present disclosure comprises a processing circuit and is configured to: determine one or more relay vehicles that must forward a message related to a vehicle; generate the message related to the vehicle, the message comprising information of the one or more relay vehicles; and send the message. By using the electronic device, wireless communication method, and computer-readable storage medium according to the present disclosure, the redundancy of information sending can be reduced while expanding the coverage range of a message so as to save on overhead and reduce interference, thereby optimizing a message sending process in the Internet of Vehicles.

Electronic device, wireless communication method and computer-readable storage medium

Various aspects of the present disclosure generally relate to wireless communication. In some aspects, an aerial user equipment (UE) may measure a first offset associated with a downlink frame based at least in part on a time when a downlink signal is received from a terrestrial base station. The aerial UE may determine a second offset corresponding to a starting time for the downlink frame at the terrestrial base station. The aerial UE may transmit an uplink message in an uplink frame using a timing advance that is based at least in part on a value of the first offset and a value of the second offset relative to a starting time associated with a global navigation satellite system frame duration. Numerous other aspects are described.

Autonomous timing advance compensation for air-to-ground communication

A fused ring compound as an FGFR and VEGFR dual inhibitor. Particularly, disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.

Fused ring compound as FGFR and VEGFR dual inhibitor

The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.

Anti-influenza virus pyrimidine derivatives

A wireless communication apparatus and method using probabilistic constellation shaping in connection with modulation. A wireless transmission device may determine a sequence of amplitude symbols from a sequence of information bits using a distribution matcher (DM) configured for probabilistic amplitude shaping. The device may further apply error correction coding to encode an information block corresponding to at least a portion of the sequence of amplitude symbols. And the device may generate a sequence of output symbols for transmission based on the encoded information block. The device may apply interleaving to one or more of the sequence of amplitude symbols, the information block, the encoded information block, or a combination of the sequence of amplitude symbols and the encoded information block, for the generating of the sequence of output symbols.

Interleaver for constellation shaping

Methods, systems, and devices for wireless communications are described. A user equipment (UE) may avoid frequent handover in small cells by triggering handover to a macro cell. The UE may determine that the UE performs a number of handovers within a time period. The UE may determine to trigger a handover to the macro cell. The UE may identify the macro cell based on measuring the macro cell during multiple handovers. The UE may determine to refrain from indicating signal measurements of small cells in a measurement report. Accordingly, a measurement report may include a signal measurement of the macro cell and omit the signal measurements of the small cells. The UE may transmit the measurement report to the small cell acting as a serving cell for the UE. Based the measurement report, the UE may receive a message initiating a handover procedure with the macro cell.

Techniques for avoiding frequent handover in small cells

An application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in preparation of a drug for treating pneumonia.

Application of monocyclic β-lactam compound in pharmacy

Growing community of inventors

Shanghai, China

Jian Li